EZH2
EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), responsible for the H3K27me3 "silencing" mark on histones. It is a master regulator of cellular identity and stem cell maintenance, and its dysregulation is a primary driver of diverse human cancers through the aberrant silencing of tumor suppressor genes.
Key Takeaways
- •EZH2 is the "lock" that permanently shuts down genes during development.
- •It is a histone methyltransferase that writes the H3K27me3 repressive mark.
- •High EZH2 activity is a hallmark of aggressive cancers, silencing the body’s natural defenses.
- •EZH2 inhibitors (e.g., Tazemetostat) are a new class of "epigenetic restart" drugs.
Basic Information
- Gene Symbol
- EZH2
- Full Name
- Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit
- Also Known As
- ENX-1KMT6KMT6AWVSWVS2
- Location
- 7q36.1
- Protein Type
- Histone Methyltransferase
- Protein Family
- Polycomb family
Related Isoforms
Key SNPs
Common marker used in GWAS panels to identify the EZH2 locus and its association with variations in biological age and hematopoietic traits.
Overview
EZH2 (Enhancer of Zeste Homolog 2) encodes the catalytic heart of the Polycomb Repressive Complex 2 (PRC2). In the world of epigenetics, if some proteins are scribes that take notes, EZH2 is the "lock" that tapes entire chapters of the genome shut. It works by adding three methyl groups to a specific spot on histones (H3K27), creating the H3K27me3 mark—the definitive signal for long-term gene silencing.
The significance of EZH2 lies in its role as a master regulator of cellular memory and identity. During development, EZH2 ensures that a muscle cell doesn’t accidentally turn on brain genes. In the context of longevity, EZH2 maintains the "quiescence" of stem cells, preventing them from exhausting themselves. However, cancer cells frequently hijack EZH2, using its silencing power to permanently shut down tumor suppressor genes, making it a premier target for therapies designed to "re-program" the cancer cell back to a healthy state.
Conceptual Model
A simplified mental model for the pathway:
EZH2 ensures that only the "correct" genes for a specific cell type remain readable.
Core Health Impacts
- • Epigenetic Silencing: The primary enzyme responsible for the H3K27me3 marks that define long-term gene repression
- • Stem Cell Maintenance: Required for the self-renewal and protection of adult stem cell pools from exhaustion
- • Oncogenesis: Hyper-activation drives the silencing of tumor suppressors in lymphoma and solid tumors
- • Cellular Identity: Ensures the stable inheritance of tissue-specific gene expression patterns across cell divisions
- • Neural Development: Essential for the temporal patterning and growth of the brain during embryogenesis
Protein Domains
SET Domain
The catalytic engine that performs the transfer of methyl groups from SAMe to histone tails.
EED-Binding
Specific region required for the interaction with EED, a subunit that activates EZH2 activity.
SANT Domain
Mediates the binding to histones and helps position the enzyme for precise methylation.
Upstream Regulators
EED / SUZ12 Activator
Obligate partners in the PRC2 complex; EZH2 has zero enzymatic activity without them.
SAMe (S-Adenosylmethionine) Activator
The universal methyl donor and absolute requirement for the EZH2 catalytic reaction.
MYC Activator
Oncogenic transcription factor that upregulates EZH2 to promote global gene silencing in cancer.
AKT1 Modulator
Phosphorylates EZH2 to modulate its activity and affinity for specific target genes.
SIRT1 Modulator
Interacts with the PRC2 complex to coordinate epigenetic silencing with cellular energy status.
Downstream Targets
H3K27me3 Activates
The primary biochemical output; the triple-methyl mark that locks chromatin.
INK4A / ARF Inhibits
Key tumor suppressor and senescence locus that is physically silenced by EZH2 activity.
HOX Genes Inhibits
Developmental patterning genes whose precise spatial expression is managed by EZH2.
Differentiation Genes Inhibits
In stem cells, EZH2 silences the genes that would force the cell to mature too early.
DNA Repair Genes Inhibits
In some cancers, over-active EZH2 can silence the machinery needed to fix DNA mutations.
Role in Aging
EZH2 is a master regulator of "epigenetic youth." Its activity determines the balance between cellular flexibility and permanent arrest. As we age, the precision of the EZH2-mediated silencing program declines, leading to the loss of stem cell function and the "noise" of biological aging.
Stem Cell Exhaustion
Age-related declines in EZH2 activity in the bone marrow and brain lead to the premature maturation and loss of stem cell pools.
Epigenetic Noise
The failure of EZH2 to maintain repressive marks allows "forbidden" genes to wake up, driving tissue dysfunction.
Senescence Breakthrough
When EZH2 levels fall with age, the *INK4A* brake is released, forcing cells into the permanent "zombie" state of senescence.
Inflammaging Link
Dysregulated EZH2 activity in immune cells contributes to the "leaky" transcriptional control of chronic aging-related inflammation.
Mitochondrial Decay
EZH2 regulates the expression of nuclear-encoded mitochondrial genes, impacting the bioenergetic reserve of older tissues.
Longevity Modifier
Highly stable EZH2 activity is associated with better preservation of tissue architecture and regenerative capacity in late life.
Disorders & Diseases
B-Cell Lymphoma
Gain-of-function EZH2 mutations (like Y641) are common drivers, permanently silencing the genes that stop B-cell growth.
Weaver Syndrome
A rare overgrowth disorder caused by germline mutations in EZH2; characterized by tall stature and intellectual disability.
Prostate Cancer
EZH2 over-expression is a primary marker of aggressive, metastatic disease and resistance to hormone therapy.
Myelodysplastic Syndrome
Loss of EZH2 function in the bone marrow leads to disorganized blood production and an increased risk of leukemia.
Breast Cancer (Triple Negative)
High EZH2 levels in TNBC drive a primitive, stem-like state that is highly resistant to standard treatments.
The Identity Paradox
EZH2 taught us that a cell's "youth" is its ability to remember who it is. In aging, cells begin to "forget" their identity because the EZH2 locks are lost. In cancer, cells "refuse" their identity because EZH2 has locked away the instructions for maturity. Both represent a failure of the same epigenetic conductor.
Interventions
Supplements
The essential fuel for EZH2; maintaining methyl donor availability is a prerequisite for epigenetic silencing.
Support the methylation cycle that provides the SAMe needed for the H3K27me3 repressive mark.
Sirtuin activator reported to modulate the PRC2 complex and potentially support epigenetic precision.
Polyphenol studied for its ability to downregulate EZH2 expression in various cancer models.
Lifestyle
Leafy greens and clean proteins ensure the EZH2 "locksmith" has the material it needs to maintain the genome.
Reported to induce healthy epigenetic remodeling, supporting the youthful maintenance of stem cell pools.
Smoking triggers broad epigenetic shifts that can overwhelm and deregulate the EZH2-mediated silencing program.
Epigenetic maintenance and histone turnover follow a circadian rhythm that impacts EZH2 stability.
Medicines
The first FDA-approved EZH2 inhibitor; used to "un-lock" the genome in epithelioid sarcoma and lymphoma.
A dual EZH1/2 inhibitor designed to provide more comprehensive blockade of Polycomb-mediated silencing.
Indirectly block EZH2 by causing the build-up of SAH, a natural competitive inhibitor of the enzyme.
Experimental drugs that break the physical link between EZH2 and its partners, EED or SUZ12.
Lab Tests & Biomarkers
Epigenetic Status
Research marker that measures the global distribution of the "locked" DNA marks created by EZH2.
A biopsy test that reflects the total "silencing load" of the genome and the activity of the PRC2 complex.
Genetic Screening
Standard diagnostic test for B-cell lymphomas to identify actionable gain-of-function mutations.
Sequencing of EZH2 and related genes to diagnose Weaver Syndrome and similar developmental conditions.
Oncology Markers
Used in pathology to assess the aggressiveness and metastatic potential of prostate and breast tumors.
Measures the "methylation potential" of the liver, which dictates the total capacity of the EZH2 system.
Hormonal Interactions
Estrogen Modulator
Reported to influence the expression density of EZH2 in breast and uterine tissues.
Androgens Upregulator
Directly drive EZH2 expression in prostate cells, contributing to the "always-on" growth of cancer.
Growth Hormone Regulator
Required for the maintenance of the total hepatic and systemic pool of epigenetic enzymes.
Thyroid Hormone Modulator
Influences the overall metabolic rate and turnover of chromatin-remodeling proteins like EZH2.
Deep Dive
Network Diagrams
EZH2: The Epigenetic Lock
The Epigenetic Locksmith: EZH2 and Gene Silencing
To understand EZH2, one must view the cell as a massive instruction manual. While some proteins highlight the important pages, EZH2 is the locksmith who tapes the unused chapters shut.
The PRC2 Engine: EZH2 is the catalytic engine of the Polycomb Repressive Complex 2 (PRC2). Its only job is to find a specific spot on the spools (histones) that hold DNA and add three methyl groups to it. This create the H3K27me3 mark—the definitive “DO NOT READ” sign for the cell.
The Identity Guardian: This silencing is essential for life. It is how a stem cell “remembers” not to turn into a brain cell if it is supposed to be a muscle cell. EZH2 locks away the irrelevant genetic programs, ensuring that cellular identity is preserved across generations of cells.
The Oncogenic Hijack: Locking the Brakes
The primary role of EZH2 in cancer is a story of a locksmith working for the wrong side.
The Hyper-active Lock: In many aggressive cancers, especially lymphomas and prostate cancer, the EZH2 gene is mutated or over-produced.
- The Over-silencing: The tumor uses EZH2 to “black out” the chapters of the DNA that would normally stop the tumor from growing (tumor suppressor genes).
- The Locked-In Growth: By permanently shutting down these “brakes,” the cancer becomes aggressive, metastatic, and resistant to standard drugs.
Tazemetostat: Re-opening the manual
The discovery that cancer is an “epigenetic lock” led to the development of a new class of drugs: EZH2 Inhibitors.
The Breakthrough: In 2020, Tazemetostat became the first drug of its kind to be approved. It physically blocks the EZH2 engine.
- The Re-opening: When a patient takes an EZH2 inhibitor, the “tape” is removed from the locked chapters of their DNA.
- The Reset: The tumor suppressor genes wake up and suddenly the cancer cell “remembers” that it is damaged and must stop dividing.
This breakthrough has proven that cancer is not just a disease of mutated DNA, but a disease of misplaced locks. By targeting the EZH2 locksmith, we can effectively “re-program” a tumor cell back into a normal, controllable state, offering a revolutionary new path toward precision oncology.
Practical Note: The Identity Lock
Silence is a signal. In healthy biology, the "silence" maintained by EZH2 is just as important as the "volume" of active genes. If you lose the EZH2 locks, your cells enter a state of "metabolic noise" where they don't know what to do. Supporting your natural methylation cycle (B12/Folate) is the definitive way to keep your cell identity locks strong.
Prostate and Breast Risk. High EZH2 levels in these tissues act like a "metabolic shield" for early tumors. If you have a family history of aggressive cancer, knowing the EZH2 status of a biopsy can help doctors decide if you need a more intensive "epigenetic reset" therapy rather than just standard treatment.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The foundational study that discovered the human EZH2 gene and established its belonging to the Polycomb group.
The landmark study that first linked EZH2 over-expression to cancer progression and metastatic potential.
Provided the first high-resolution insights into the structural architecture of the PRC2 complex and its catalytic engine.
Demonstrated that maintaining EZH2 function is a requirement for preserving the regenerative capacity of aging tissues.
Clinical review of the breakthrough therapy that proved epigenetic reprogramming is a viable strategy for treating human tumors.